Acasti Pharma Inc. (ACST)
Symbol Info
Listed Symbol ACST
Name Acasti Pharma Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2019-03-31
Latest Fiscal Revenue $-
Latest Fiscal EPS $-0.71
Price Info
21 Day Moving Average $2.0219
21 Day EMA $2.010820
50 Day Moving Average $2.0046
50 Day EMA $1.938890
200 Day EMA $1.457290
200 Day Moving Average 1.316120
52 Week High $2.95
52 Week Low $0.60
52 Week Change $80.833300
Alpha 0.003932
Beta 1.3557
Standard Deviation 0.277745
R2 0.028126
Periods 60
Share Information
10 Day Average Volume 712,927
20 Day Average Volume 744,360
30 Day Average Volume 893,152
50 Day Average Volume 1,285,625
Outstanding Shares 85,188,095
Float Shares 85,188,095
Percent Float 100.00%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 20
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 187,823
Institute Holdings Percent 3.500000
Institute Sold Previous 3 Months 66,861
Insider Holdings Date
Insider Bought Previous 3 Months -
Insider Holdings Percent -
Insider Sold Previous 3 Months -
Insiders Shares Owned -
Price Change
7 Day Price Change $0.3000001
7 Day Percent Change 16.04%
21 Day Price Change $0.0600002
21 Day Percent Change 2.84%
30 Day Price Change $-0.02
30 Day Percent Change -0.91%
Month To Date Price Change $0.2800
Month To Date Percent 14.81%
90 Day Price Change $0.770000
90 Day Percent Change 55.00%
Quarter To Date $0.280000
Quarter To Date Percent 14.81%
180 Day Price Change $1.212900
180 Day Percent Change 126.73%
200 Day Price Change $1.120000
200 Day Percent Change 106.67%
Year To Date $1.338100
Year To Date Percent 160.85%
Profile
Description Acasti Pharma Inc is a biopharmaceutical company operating in Canada. It focuses on the research, development, and commercialization of prescription drugs using omega-3 fatty acids derived from krill oil. The key product candidate of the company, CaPre is developed for the treatment of severe hypertriglyceridemia, which is a condition characterized by abnormally high levels of triglycerides in the bloodstream. Its only operating segment being the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.
Details
Issue Type CS
Market Cap $184,858,166
Sec Type EQS
Auditor KPMG LLP
Total Shares Outstanding 84,817,745
CEO Janelle D'Alvise
Employees 28
Last Audit UE
Classification
CIK 0001444192
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 545, Promenade du Centropolis
Suite 100
Laval, QC H7T 0A3
Website http://www.acastipharma.com
Facisimile +1 450 686-2505
Telephone +1 438 399-7114
Email ACST@crescendo-ir.com
Key Ratios
Profitability
EBIT Margin -
EBITDA Margin -
Pre-Tax Profit Margin -
Profit Margin Cont -
Gross Margin -
Profit Margin TOT -
Income Statements
Revenue $-
Revenue Per Share $-
Revenue 3 Years $-
Revenue 5 Years $-
Valuation Measures
PE Ratio -
Enterprise Value $140,475,562
Price To Sales -
Price To Free Cash -7
PE High Last 5 Years -
Price To Book 58.0
Price To Cash Flow -
PE Low Last 5 Years -
Price To Tangible Book 58.0
Financial Strength
Total Debt To Equity 0.5
Int Coverage -152.6
Current Ratio 1.6
Leverage Ratio 5.0
Quick Ratio 1.6
Long Term Debt To Capital -
Assets
Receivables Turnover -
Invoice Turnover -
Assets Turnover -
Management Effectiveness
Return Assets -170.8
Return On Equity -1,006.68
Return On Capital -756.24
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
ACST
Acasti Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.